Lixisenatide vs Retatrutide

Lixisenatide (brand names Adlyxin and Soliqua) is an FDA-approved GLP-1 receptor agonist used to treat type 2 diabetes, taken as an injection. Retatrutide, still in development, is a triple-action drug that targets GIP, GLP-1, and glucagon receptors, but it has not yet been approved for any use.

AI summary of the sources below.